Loading
A phase 2 trial of Acitretin and Vemurafenib in Melanoma, run by University of Arizona, recorded as terminated on the registry.
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma is a phase 2 interventional study registered as NCT02050321 by University of Arizona, with 2 participants recorded, started 2013-12 and due to reach its primary completion in 2014-12. Interventions recorded: Acitretin, Vemurafenib. Conditions recorded: Malignant Melanoma.
Linked to the drug Acitretin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.